Company Encyclopedia
View More
name
Hims & Hers Health
HIMS.US
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care.
373.06 B
HIMS.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
B
Health Care ServicesIndustry
Industry Ranking5/80
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE26.21%A
    • Profit Margin6.05%B
    • Gross Margin73.80%A
  • Growth ScoreA
    • Revenue YoY78.02%A
    • Net Profit YoY32.13%B
    • Total Assets YoY270.82%A
    • Net Assets YoY32.03%A
  • Cash ScoreA
    • Cash Flow Margin1652.57%B
    • OCF YoY78.02%A
  • Operating ScoreA
    • Turnover1.56A
  • Debt ScoreD
    • Gearing Ratio73.99%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 23,187 Shares

    Hims & Hers Health CFO Oluyemi Okupe sold 23,187 shares at $36.81 each, totaling $853,513.47, reducing his stake by 24.82%. The company announced a $250 million share repurchase plan, indicating undervaluation. Recent earnings missed estimates, but revenue rose 49.2% year-over-year. The stock's price has fluctuated, with a 12-month low of $21.36 and high of $72.98. Institutional investors are actively trading the stock.

    Market Beat·
    US
    HIMS
    -6.17%
    Market Beat·
    US
    HIMS
    -6.17%

    Hims & Hers Health CFO Sells Shares

    Reporter NameOkupe OluyemiRelationshipChief Financial Officer, 10% OwnerTypeSellAmount$853,490SEC FilingForm 4Okupe Oluyemi, Chief Financial Officer and 10% Owner of Hims & Hers Health, sold 23,187 shares of Class A Common Stock on November 17, 2025, at an average weighted price of $36.809 per share, totaling $853,490. Following the transaction, Oluyemi directly owns 70,232 shares and indirectly owns 7,853 shares through a separate property trust. The sales were conducted under a pre-arranged Rule 10b5-1 trading plan.SEC Filing: Hims & Hers Health, Inc. [ HIMS ] - Form 4 - Nov. 19, 2025

    TradingView·
    US
    HIMS
    -6.17%
    TradingView·
    US
    HIMS
    -6.17%

    Renaissance Group LLC Acquires 87,755 Shares of Hims & Hers Health, Inc. $HIMS

    Renaissance Group LLC increased its holdings in Hims & Hers Health, Inc. by 99% in Q2, acquiring an additional 87,755 shares, totaling 176,384 shares valued at $8.79 million. Institutional investors now own 63.52% of the stock. Hims & Hers Health reported Q3 earnings of $0.06 per share, missing estimates, with revenue up 49.2% year-over-year. The company announced a $250 million stock buyback program, indicating potential undervaluation. Recent insider sales were also reported.

    Market Beat·
    US
    HIMS
    -6.17%
    Market Beat·
    US
    HIMS
    -6.17%

    Hims & Hers (HIMS) Investors Keep the Faith as Stock Slides 15%

    Hims & Hers Health (HIMS) stock has dropped over 15% since last week, following its Q3 update. Concerns include GLP-1 dependence, margin pressure, and increased spending, which may challenge the telehealth business's sustainability. Despite the decline, investors remain hopeful.

    Tip Ranks·
    US
    HIMS
    -6.17%
    Tip Ranks·
    US
    HIMS
    -6.17%

    Mizuho Securities Reaffirms Their Sell Rating on Hims & Hers Health (HIMS)

    Mizuho Securities has reaffirmed its Sell rating on Hims & Hers Health (HIMS) with a price target of $30.00. Additionally, Bank of America Securities also issued a Sell rating, while Truist Financial maintained a Hold rating on the same day.

    Tip Ranks·
    US
    HIMS
    -6.17%
    Tip Ranks·
    US
    HIMS
    -6.17%
    Posts
    View More